1 Supplement

2	Global incidence and mortality of neonatal sepsis: systematic review and meta-analysis
3	Fleischmann-Struzek C, MD* ¹ , Reichert F, MD* ^{2,3,4} , Cassini A, MD ⁵ , Horner R ² , Harder T,
4	MD ² , Markwart R, PhD ² , Troendle M ² , Savova Y ² , Prof. Kissoon N, MD ⁶ , Prof. Schlattmann
5	P, MD ⁷ , Prof. Reinhart K, MD ^{8,9,10} , Prof. Allegranzi B, MD ⁵ , Eckmanns T, MD ²
6	*contributed equally
7	
8	1 Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany
9	2 Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
10	3 Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute, Berlin,
11	Germany
12	4 European Programme for Intervention Epidemiology Training (EPIET), European Centre
13	for Disease Prevention and Control (ECDC), Stockholm, Sweden
14	5 Infection Prevention and Control Hub, Integrated Health Services, World Health
15	Organization HQ, Geneva, Switzerland
16	6 University of British Columbia and British Columbia Children's Hospital, Vancouver, BC,
17	Canada
18	7 Institute for Medical Statistics, Computer Science and Data Science, Jena University
19	Hospital, Jena, Germany
20	8 Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK),
21	Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-
22	Universität zu Berlin, Berlin, Germany

- 23 9 Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Germany
- 24 10 Institute of Infectious Diseases and Infection Control, Jena University Hospital, Jena,
- 25 Germany
- 26
- 27 This supplement forms part of the original submission.
- 28 We post it as supplied by the authors.

29 Supplement: Search strategy

30 **Pubmed (and adapted for all other databases)**

- 31 (((sepsis[Title] OR septic*[Title]) AND (Developing Countries*[Title/Abstract] OR 32 Africa*[Title/Abstract] OR Asia*[Title/Abstract] OR Caribbean[Title/Abstract] OR West 33 Ind*[Title/Abstract] OR South America*[Title/Abstract] OR Latin America*[Title/Abstract] 34 OR Central America*[Title/Abstract] OR Afghanistan* OR Albania*[Title/Abstract] OR 35 Algeria*[Title/Abstract] OR Angola*[Title/Abstract] OR Antigua*[Title/Abstract] OR 36 Barbuda*[Title/Abstract] OR Argentina*[Title/Abstract] OR Armenia[Title/Abstract] OR 37 Armenian[Title/Abstract] OR Aruba*[Title/Abstract] OR Azerbaijan*[Title/Abstract] OR 38 Bahrain*[Title/Abstract] OR Bangladesh*[Title/Abstract] OR Barbados*[Title/Abstract] OR 39 Benin*[Title/Abstract] OR Byelarus[Title/Abstract] OR Byelorussian[Title/Abstract] OR 40 Belarus*[Title/Abstract] OR Belorussian[Title/Abstract] OR Belorussia[Title/Abstract] OR 41 Beliz*[Title/Abstract] OR Bhutan*[Title/Abstract] OR Bolivia*[Title/Abstract] OR 42 Bosnia*[Title/Abstract] OR Herzegovina*[Title/Abstract] OR Hercegovina*[Title/Abstract] 43 OR Botswana*[Title/Abstract] OR Brasil*[Title/Abstract] OR Brazil*[Title/Abstract] OR 44 Bulgaria*[Title/Abstract] OR Burkina Faso*[Title/Abstract] OR Burkina 45 Fasso*[Title/Abstract] OR Upper Volta*[Title/Abstract] OR Burundi*[Title/Abstract] OR 46 Urundi*[Title/Abstract] OR Cambodia*[Title/Abstract] OR Khmer Republic*[Title/Abstract] 47 OR Kampuchea*[Title/Abstract] OR Cameroon*[Title/Abstract] OR 48 Cameroons*[Title/Abstract] OR Cameron*[Title/Abstract] OR Cape Verde[Title/Abstract] 49 OR Central African Republic*[Title/Abstract] OR Chad*[Title/Abstract] OR 50 Chile*[Title/Abstract] OR China*[Title/Abstract] OR Colombia*[Title/Abstract] OR 51 Comoros*[Title/Abstract] OR Comoro Island*[Title/Abstract] OR Comores[Title/Abstract] 52 OR Mayotte[Title/Abstract] OR Congo*[Title/Abstract] OR Zaire*[Title/Abstract] OR Costa 53 Rica*[Title/Abstract] OR Cote d'Ivoire[Title/Abstract] OR Ivory Coast[Title/Abstract] OR 54 Croatia*[Title/Abstract] OR Cuba*[Title/Abstract] OR Cyprus*[Title/Abstract] OR 55 Czechoslovakia*[Title/Abstract] OR Czech Republic*[Title/Abstract] OR 56 Czechia*[Title/Abstract] OR Slovakia*[Title/Abstract] OR Slovak Republic*[Title/Abstract] 57 OR Djibouti*[Title/Abstract] OR French Somaliland*[Title/Abstract] OR 58 Dominica*[Title/Abstract] OR Dominican Republic*[Title/Abstract] OR East 59 Timor*[Title/Abstract] OR East Timur*[Title/Abstract] OR Timor Leste*[Title/Abstract] OR 60 Ecuador*[Title/Abstract] OR Egypt*[Title/Abstract] OR United Arab
 - 61 Republic*[Title/Abstract] OR El Salvador*[Title/Abstract] OR Eritrea*[Title/Abstract] OR

62	Estonia*[Title/Abstract] OR Ethiopia*[Title/Abstract] OR Fiji*[Title/Abstract] OR
63	Gabon*[Title/Abstract] OR Gabonese Republic[Title/Abstract] OR Gambia*[Title/Abstract]
64	OR Gaza*[Title/Abstract] OR Georgia Republic*[Title/Abstract] OR Georgian
65	Republic*[Title/Abstract] OR Ghana*[Title/Abstract] OR Gold Coast*[Title/Abstract] OR
66	Greece[Title/Abstract] OR Grenada*[Title/Abstract] OR Guatemala*[Title/Abstract] OR
67	Guinea*[Title/Abstract] OR Guam*[Title/Abstract] OR Guiana*[Title/Abstract] OR
68	Guyana*[Title/Abstract] OR Haiti*[Title/Abstract] OR Honduras*[Title/Abstract] OR
69	Hungar*[Title/Abstract] OR India OR Maldiv*[Title/Abstract] OR Indonesia*[Title/Abstract]
70	OR Iran*[Title/Abstract] OR Iraq*[Title/Abstract] OR Isle of Man[Title/Abstract] OR
71	Jamaica*[Title/Abstract] OR Jordan*[Title/Abstract] OR Kazakhstan*[Title/Abstract] OR
72	Kazakh*[Title/Abstract] OR Kenya*[Title/Abstract] OR Kiribati*[Title/Abstract] OR
73	Korea*[Title/Abstract] OR Kosovo*[Title/Abstract] OR Kyrgyzstan*[Title/Abstract] OR
74	Kirghizia*[Title/Abstract] OR Kyrgyz Republic*[Title/Abstract] OR Kirghiz*[Title/Abstract]
75	OR Kirgizstan*[Title/Abstract] OR Lao PDR*[Title/Abstract] OR Laos*[Title/Abstract] OR
76	Latvia*[Title/Abstract] OR Lebanon*[Title/Abstract] OR Lesotho*[Title/Abstract] OR
77	Basutoland*[Title/Abstract] OR Liberia*[Title/Abstract] OR Libya*[Title/Abstract] OR
78	Lithuania*[Title/Abstract] OR Macedonia*[Title/Abstract] OR Madagascar*[Title/Abstract]
79	OR Malagasy Republic*[Title/Abstract] OR Malaysia*[Title/Abstract] OR
80	Malaya*[Title/Abstract] OR Malay*[Title/Abstract] OR Sabah*[Title/Abstract] OR
81	Sarawak*[Title/Abstract] OR Malawi*[Title/Abstract] OR Nyasaland OR
82	Mali*[Title/Abstract] OR Malta*[Title/Abstract] OR Marshall Island*[Title/Abstract] OR
83	Mauritania*[Title/Abstract] OR Mauritius*[Title/Abstract] OR Agalega
84	Island*[Title/Abstract] OR Mexico*[Title/Abstract] OR Micronesia*[Title/Abstract] OR
85	Middle East*[Title/Abstract] OR Moldova*[Title/Abstract] OR Moldovia*[Title/Abstract]
86	OR Moldovian*[Title/Abstract] OR Mongolia*[Title/Abstract] OR
87	Montenegro*[Title/Abstract] OR Morocco*[Title/Abstract] OR Ifni*[Title/Abstract] OR
88	Mozambique*[Title/Abstract] OR Myanmar*[Title/Abstract] OR Myanma*[Title/Abstract]
89	OR Burma*[Title/Abstract] OR Namibia*[Title/Abstract] OR Nepal*[Title/Abstract] OR
90	Netherlands Antilles[Title/Abstract] OR New Caledonia*[Title/Abstract] OR
91	Nicaragua*[Title/Abstract] OR Niger*[Title/Abstract] OR Nigeria*[Title/Abstract] OR
92	Northern Mariana Island*[Title/Abstract] OR Oman*[Title/Abstract] OR Muscat OR
93	Pakistan*[Title/Abstract] OR Palau*[Title/Abstract] OR Palestine*[Title/Abstract] OR
94	Panama*[Title/Abstract] OR Paraguay*[Title/Abstract] OR Peru*[Title/Abstract] OR
95	Philippines*[Title/Abstract] OR Philipines*[Title/Abstract] OR Philipines*[Title/Abstract]

96 OR Phillippines*[Title/Abstract] OR Poland*[Title/Abstract] OR Portugal*[Title/Abstract] 97 OR Puerto Rico*[Title/Abstract] OR Romania*[Title/Abstract] OR Rumania*[Title/Abstract] 98 OR Roumania*[Title/Abstract] OR Russia*[Title/Abstract] OR Russian*[Title/Abstract] OR 99 Rwanda*[Title/Abstract] OR Ruanda*[Title/Abstract] OR Saint Kitts*[Title/Abstract] OR St 100 Kitts*[Title/Abstract] OR Nevis*[Title/Abstract] OR Saint Lucia*[Title/Abstract] OR St 101 Lucia*[Title/Abstract] OR Saint Vincent*[Title/Abstract] OR St Vincent*[Title/Abstract] OR 102 Grenadines*[Title/Abstract] OR Samoa*[Title/Abstract] OR Samoan Island*[Title/Abstract] 103 OR Navigator Island*[Title/Abstract] OR Navigator Island*[Title/Abstract] OR Sao 104 Tome*[Title/Abstract] OR Saudi Arabia*[Title/Abstract] OR Senegal*[Title/Abstract] OR 105 Serbia*[Title/Abstract] OR Montenegro*[Title/Abstract] OR Seychelles*[Title/Abstract] OR 106 Sierra Leone*[Title/Abstract] OR Slovenia*[Title/Abstract] OR Sri Lanka*[Title/Abstract] 107 OR Ceylon*[Title/Abstract] OR Solomon Island*[Title/Abstract] OR 108 Somalia*[Title/Abstract] OR South Africa*[Title/Abstract] OR Sudan*[Title/Abstract] OR 109 Suriname*[Title/Abstract] OR Surinam*[Title/Abstract] OR Swaziland*[Title/Abstract] OR 110 eSwatini*[Title/Abstract] OR Syria*[Title/Abstract] OR Tajikistan*[Title/Abstract] OR 111 Tadzhikistan*[Title/Abstract] OR Tadjikistan*[Title/Abstract] OR Tadzhik*[Title/Abstract] 112 OR Tanzania*[Title/Abstract] OR Thailand*[Title/Abstract] OR Togo*[Title/Abstract] OR 113 Togolese Republic*[Title/Abstract] OR Tonga*[Title/Abstract] OR Trinidad*[Title/Abstract] 114 OR Tobago*[Title/Abstract] OR Tunisia*[Title/Abstract] OR Turk*[Title/Abstract] OR 115 Turkmenistan*[Title/Abstract] OR Turkmen*[Title/Abstract] OR Uganda*[Title/Abstract] 116 OR Ukrain*[Title/Abstract] OR Uruguay*[Title/Abstract] OR USSR*[Title/Abstract] OR 117 Soviet Union*[Title/Abstract] OR Union of Soviet Socialist Republics*[Title/Abstract] OR 118 Uzbekistan*[Title/Abstract] OR Uzbek*[Title/Abstract] OR Vanuatu*[Title/Abstract] OR 119 New Hebrides*[Title/Abstract] OR Venezuela*[Title/Abstract] OR Vietnam*[Title/Abstract] 120 OR Viet Nam*[Title/Abstract] OR West Bank*[Title/Abstract] OR Yemen*[Title/Abstract] 121 OR Yugoslavia*[Title/Abstract] OR Zambia*[Title/Abstract] OR Zimbabw*[Title/Abstract] 122 OR Rhodesia*[Title/Abstract] OR Cook Island*[Title/Abstract] OR Marshall 123 Island*[Title/Abstract] OR Nauru*[Title/Abstract] OR Niue*[Title/Abstract] OR Papua New 124 Guinea*[Title/Abstract] OR Tuvalu*[Title/Abstract] OR Vanuatu*[Title/Abstract]) AND 125 ("1979/01/01"[PDat] : "3000/12/31"[PDat])) OR ((sepsis[Title] OR septic*[Title]) AND (epidemiolog*[Title] OR incidence[Title] OR burden[Title] OR prevalence[Title]) AND 126 127 ("2016/05/01"[PDat] : "3000/12/31"[PDat]))) NOT "animals"[MeSH:noexp] 128

129 Supplement: Data extraction strategy

- 130 Extracted data included: Author, country, years of observation, study design and setting,
- 131 sepsis definition, patient population (inborn/outborn, relevant risk groups [low birth weight
- 132 (LBW), very low birth weight neonates (VLBW), preterm neonates]), exclusion criteria, live
- 133 births, sepsis cases, population denominator, sepsis incidence, prevalence, mortality
- 134 (proportion of neonatal sepsis patients that died), mortality per 100 000 live births, sepsis-
- 135 attributable mortality, hospital length of stay, underlying infections, proportion of culture-
- 136 proven sepsis, isolated pathogens, and antimicrobial resistance.

- 138 If results were reported by year, respective years were extracted separately. If only the
- 139 number of inborn live births was known, sepsis cases within this population were extracted.
- 140 Trial data were extracted if interventions did not target sepsis or were only from observation
- 141 periods prior to the intervention. For nationwide studies with missing population
- 142 denominator, the number of live births was extracted from national census registries.

143 Supplement eFig. 1: Incidence of early-onset sepsis per 100 000 livebirths by sub-group

Study and observation period	Cases per 100 000 livebirths	Incidence	95% CI
Normal Birth Weight Chacko 2000 - 2001 Schrag 2004 - 2007 Swamkar 2008 - 2010 Random effects model Heterogeneity: $I^2 = 97\%$, $\tau^2 = 1.4189$, $\chi^2_2 = 59.26$ ($p < 0.01$)	•	482.32 3074.26 320.00 818.08	[177.20; 1046.82] [2695.60; 3489.88] [138.25; 629.55] [204.47; 3213.88]
Low Birth Weight Chacko 2000 - 2001 Schrag 2004 - 2007 Swamkar 2008 - 2010 Random effects model Heterogeneity: $l^2 = 77\%$, $\tau^2 = 0.0890$, $\chi_2^2 = 8.6$ ($p = 0.01$)	₩ ₩ ₩	4444.44 7758.62 4357.80 5421.46	[2655.01; 6933.36] [5715.22; 10244.09] [3101.99; 5932.61] [3706.55; 7865.01]
Very Low Birth Weight Chacko 2000 - 2001 Schrag 2004 - 2007 Swamkar 2008 - 2010 Random effects model Heterogeneity: $I^2 = 75\%$, $\tau^2 = 0.3106$, $\chi^2_2 = 7.92$ ($\rho = 0.02$)		12765.96 31428.57 12871.29 17128.77	[6773.85; 21238.00] [16851.72; 49288.00] [8583.14; 18288.19] [9192.09; 29678.53]
Term Chacko 2000 - 2001 Schrag 2004 - 2007 Swamkar 2008 - 2010 Random effects model Heterogeneity: $l^2 = 97\%$, $\tau^2 = 1.4822$, $\chi^2_2 = 69.65$ ($p < 0.01$)	6	492.96 3171.36 312.72 821.28	[198.42; 1013.03] [2794.11; 3584.01] [143.09; 592.80] [200.52; 3300.24]
Preterm Chacko 2000 - 2001 Schrag 2004 - 2007 Swarnkar 2008 - 2010 Random effects model Heterogeneity: $I^2 = 57\%$, $\chi^2 = 0.0379$, $\chi^2_2 = 4.67$ ($p = 0.10$)	0 10 000 30 000 50	8978.33 13268.61 9051.72 10251.73	[6095.47; 12639.68] [9692.78; 17567.12] [7025.62; 11432.56] [7890.76; 13217.74]

144

145 Abbreviations: 95% CI 95% confidence interval

146 Supplement eFig. 2: Incidence of neonatal sepsis (early and late-onset sepsis combined)

147 per 100 000 livebirths by setting

Study and observation period	Cases per 100 000 livebirths	Incidence	95% CI
Community Bang 1995 - 1996 Bang 1996 - 2003 Bartlett 1988 - 1989 Kayom 2012 - 2012 Niswade 2006 - 2007 Panigrahi 2002 - 2005 Random effects model Heterogeneity. $I^2 = 99\%, \tau^2 = 0.3260, p < 0.01$	*-*- *-*- *	- 17038.01 10478.36 4863.22 11041.01 8831.65 4096.02 8549.33	[14436.34; 19897.30] [9663.87; 11336.92] [2804.96; 7777.58] [7811.98; 15019.88] [7212.05; 10677.98] [3756.92; 4456.50] [5520.31; 13011.49]
Hospital Chacko 2000 - 2001 Ghiorghis 1992 - 1993 Hartman 2000 - 2000 Hartman 2005 - 2005 Investigators of the DeNIS collaboration 2011 - 2014 Kaushik Khatua 1982 - 1983 López 2009 - 2009 Martin 1994 - 2002 Mondal 1988 - 1989 Nazer 1977 - 1977 Nazer 1977 - 1977 Nazer 1977 - 1977 Nazer 1977 - 1977 Nazer 1977 - 1977 Schrag 2004 - 2007 Shin 1997 - 1997 Shin 1998 - 1998 Shin 1995 - 1995 Random effects model		3729 20 3343.74 539.37 970.46 2181.96 3005.33 1097.07 2927.18 5000.00 1548.95 302.66 994.15 3800.74 3438.10 3973.43 4543.11 3869.27 2571.14 3869.27 2571.14 3869.27	[2889.68; 4728.70] [2927.09; 3801.42] [524.46; 554.60] [950.59; 990.64] [2086.78; 2280.28] [2311.77; 3836.30] [885.28; 1343.78] [2771.54; 3089.09] [4616.84; 5405.17] [1151.79; 2037.05] [98.34; 704.89] [3634.76; 3972.11] [2824.33; 4137.21] [3559.22; 4421.03] [4090.77; 5029.94] [3456.93; 4315.69] [2325.68; 2941.68] [3456.83; 353.66] [3456.00; 2914.14]
Random effects model Heterogeneity: $l^2 = 100\%$, $t^2 = 1.0755$, $p = 0$ Residual heterogeneity: $l^2 = 100\%$, $r^2 = 1.0755$, $p = 0$	0 5000 10000 15000 200	2 823.78	[1892.20; 4194.38]

148

149 Abbreviations: 95% CI 95% confidence interval

150 Supplement eFig. 3: Incidence of neonatal sepsis (early and late-onset sepsis combined)

151 per 100 000 livebirths by income level

Study and observation period	Country	Cases per 100 000 livebirths	Incidence	95% CI
Low Income Ghiorghis 1992 - 1993 Kayom 2012 - 2012 Random effects model Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.7809$, $p < 0.01$	Ethiopia Uganda		3343.74 11041.01 6086.43	[2927.09; 3801.42] [7811.98; 15019.88] [1843.07; 18279.98]
$\label{eq:second} \begin{array}{l} \mbox{Middle income} \\ \mbox{Bang 1995 - 1996 1995 - 2003 \\ \mbox{Barliett 1988 - 1989 Chacko 2000 - 2001 \\ \mbox{Investigators of the DeNIS collaboration 2011 - 2014 \\ \mbox{Kaushk } \\ \mbox{Kaushk 1982 - 1983 Lopez 2009 - 2009 \\ \mbox{Mondal 1988 - 1983 Lopez 2009 - 2009 \\ \mbox{Mondal 1988 - 1983 Lopez 2006 - 2007 \\ \mbox{Nazer 1977 - 1977 \\ \mbox{Nazer 1978 - 1978 } \\ \mbox{Niswade 2006 - 2007 \\ \mbox{Panigrafi 2002 - 2005 \\ \mbox{Pavan Kumar 2013 - 2015 \\ \mbox{Schrag 2004 - 2007 \\ \mbox{Random effects model \\ \mbox{Heterogeneity. } r^2 = 99\%, r^2 = 0.9563, p = 0 \\ \end{array} }$	India India Guatemala India India India India Nicaragua India Jordan Jordan Jordan India India India India South Africa	***	17038.01 10478.36 4863.22 3729.20 2181.96 3005.33 1097.07 2927.18 1548.95 302.66 994.15 8831.65 3800.74 4096.02 3436.10 3973.43 3195.32	[14436.34; 19897.30] [9663.87; 11336.92] [2804.96; 7777.58] [2889.68; 4728.70] [2086.78; 2280.28] [2311.77; 3836.30] [885.28; 1343.78] [2771.54; 3089.09] [1151.79; 2037.05] [98.34; 704.89] [580.17; 1586.98] [7212.05; 10677.98] [3634.76; 3972.11] [3756.92; 4456.50] [2824.33; 4137.21] [3559.22; 4421.03] [1991.22; 5089.74]
High Income Hartman 2000 - 2000 Hartman 2005 - 2005 Martin 1994 - 2002 Shin 1998 - 1997 Shin 1998 - 1998 Shin 1999 - 1999 Watson 1995 - 1995 Random effects model Heterogeneity: $l^2 = 100\%$, $\tau^2 = 1.2103$, $p = 0$	US US Antigua and Barbuda South Korea South Korea South Korea US	φ	539.37 970.46 5000.00 4543.11 3869.27 2571.14 360.29 1722.28	[524.46; 554.60] [950.59; 990.64] [4616.84; 5405.17] [4090.77; 5029.94] [3456.93; 4315.69] [2235.68; 2941.68] [345.68; 375.36] [769.25; 3810.71]
Random effects model Heterogeneity: $I^2 = 100\%$, $\tau^2 = 1.0755$, $p = 0$ Residual heterogeneity: $I^2 = 100\%$, $p = 0$		0 5000 10000 15000 200	2823.78	[1892.20; 4194.38]

¹⁵³ Abbreviations: 95% CI 95% confidence interval

154 Supplement eFig. 4: Mortality of neonatal sepsis cases (early-onset sepsis, late-onset

155 sepsis, and early and late-onset sepsis combined)

Study and observation period	Deceased cases	Sepsis cases	Deaths per 100 sepsis cases	Mortality (%)	95% CI
EOS Chacko 2000 - 2001 Investigators of the DeNIS collaboration 2011 - 2014 Panigrah 2002 - 2005 Schrag 2004 - 2007 Swarnkar 2008 - 2010 Random effects model Heterogeneity: $l^2 = 90\%$, $\tau^2 = 0.3668$, $\rho < 0.01$	7 324 8 17 13	36 1351 36 289 72	+ = * *	19.44 [23.98 [2 22.22 [1 5.88] 18.06 [16.35]	8.19; 36.02] 21.73; 26.35] (0.12; 39.15] [3.46; 9.25] 9.98; 28.89] 9.75; 26.13]
LOS Investigators of the DeNIS collaboration 2011 - 2014 Panigrahi 2002 - 2005 Schrag 2004 - 2007 Random effects model Heterogeneity: $l^2 = 98\%$, $\tau^2 = 1.6452$, $p < 0.01$	172 22 1	583 462 34	*	29.50 [2 4.76 2.94 [9.14 [25.83; 33.39] [3.01; 7.12] 0.07; 15.33] 2.06; 32.48]
EOS & LOS Bang 1995 - 1996 Investigators of the DeNIS collaboration 2011 - 2014 Kaushik Khatua 1982 - 1983 Mondal 1988 - 1989 Nazer 1977 - 1977 Nazer 1978 - 1978 Panigrahi 2002 - 2005 Schrag 2004 - 2007 Watson 1995 - 1995 Random effects model Heterogeneity: $I^2 = 97\%$, $x^2 = 0.8994$, $p < 0.01$	24 496 15 53 5 2 4 30 18 235	130 1934 62 92 50 5 17 498 323 2280		18.46 [1 25.65 [2 24.19 [1 57.61 [4 40.00 [23.53 [6.02 5.57] 10.31 [17.62 [1	2 20; 26 21] 3 71; 27.65] 4 22; 36.74] 6 86; 67.85] 3 33; 21.81] 5 27; 85.34] 6 81; 49.90] [4.10; 8.49] [3.34; 8.66] 9.09; 11.63] 0.25; 28.62]

156

157 Abbreviations: 95% CI 95% confidence interval, EOS early-onset sepsis, LOS late-onset sepsis

159 Supplement eFig. 5: Proportion of culture-proven sepsis (early-onset sepsis, late-onset

160 sepsis, and early and late-onset sepsis combined)

161

36 160 289 697 171 72		[25.51; 59.24] [0.69; 6.28] [12.09; 17.48] [12.09; 17.48] [0.01; 3.22] [39.31; 63.35] [2.73; 37.05]
479 34 171	1127 58.82 24.56 27.45	[8.58; 14.45] [40.70; 75.35] [18.31; 31.72] [8.88; 59.49]
65 225 109 92 50 112 1899 517 388 107 323 1934 868 96	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} [30.85; 55.96] \\ [27.63; 40.36] \\ [27.63; 40.36] \\ [27.67; 46.47] \\ [49.04; 69.88] \\ [21.21; 48.77] \\ [52.85; 71.47] \\ [39.16; 43.64] \\ [8.00; 14.47] \\ [18.15; 35.55] \\ [11.44; 19.56] \\ [14.17; 19.23] \\ [24.04; 43.68] \\ [24.04; 43.68] \\ [23.50; 41.42] \end{array}$
	1 112 1 1899 1 1899 1 17 1 38 1 107 1 38 1 107 1 38 1 107 1 127 1 127 1 127 1 127 1 129 1 12	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

Supplement eTab. 1: Individual study characteristics

First author, publication year	Country, WHO region	Income level	Study period	Study design	Study setting and included patients	Sepsis case definition	Type of sepsis					
hospital-based												
Chacko, 2005(18)	India, South-East Asia Region	Middle	2000- 2001	Single center prospective cohort study, hospital records registry	Tertiary care teaching hospital, neonatal unit, inborn, no exclusion criteria stated, subgroups: LBW and VLBW	Positive blood/cerebrospinal fluid cultures or developing clinical sepsis defined as any feature suggestive of sepsis such as altered body temperature, tachypnea/apnea, lethargy, poor feeding, shock or metabolic acidosis	EOS+LO S, EOS (≤72h), LOS (>72h)					
Ghiorghis, 1997(19)	Ethiopia, African Region	Low	1992- 1993	Single center retrospective cohort study, hospital records registry	Referral children's hospital, neonatal unit, inborn, no exclusion criteria stated	Clinical manifestations and/or positive blood culture (definition according to Alojipan & Andrews 1975(56): "Clinical manifestations considered for infants with infection included cyanosis, tachypnea, retractions, apnea, tachycardia, hypo- or hyperthermia, lethargy, irritability, seizures, feeding problems, vomiting, diarrhea, abdominal distention, jaundice, hepatosplenomegaly, and weight loss.")	EOS+LO S					
Goulart, 2006(20)	Brazil, Region of the Americas	Middle	2004	Single center prospective case-control study, active observation	Referral hospital, NICU, no exclusion criteria stated	Definition according to Goldstein consensus criteria(11) Sepsis: SIRS in the presence of or as a result of suspected or proven infection; SIRS: presence of at least 2/4 criteria, one of which must be abnormal temperature or leukocyte count:	EOS (≤72h)					

						 Corebody temperature of 38.5° C of 36° C Tachycardia, defined as a mean heart rate 2 SD above normal for age OR bradycardia OR otherwise unexplained persistent depression over a 0.5-hour time period Mean respiratory rate > 2 SD above normal for age or mechanical ventilation for an acute process Leukocyte count elevated or depressed for age or > 10% immature neutrophils; Infection: suspected or proven (by positive culture, tissue stain, or polymerase chain reaction test) infection caused by any pathogen OR clinical syndrome associated with a high probability of infection;	
Hartman, 2013(21)	USA, Region of the Americas	High	2000 2005	Multicenter retrospective cohort study, hospital records registry	All non-federal hospitals in 7 states representative of the US, Inborn and outborn, no exclusion criteria stated	ICD-based implicit case identification (ICD-9–CM codes for both infection and acute organ failure)	EOS+LO S
Investigators	India,	Middle	2011-	Multicenter	3 Level III-care centres with	Culture-positive sepsis:	EOS+LO

of the Delhi	South-East	2014	prospective	NICUs,	Isolation of a recognised pathogen from	S, EOS
Neonatal	Asia Region		cohort study	inhorn	blood, cerebrospinal fluid, or other body	(≤/2h), LOS
Study			conort study,	incom,	on the basis of clinical features or maternal	(>72h)
(DeNIS)			active observation	exclusion criteria: Neonates	or perinatal risk factors along with	(>7211)
collaboration.				requiring rehospitalisation after	treatment involving appropriate type and	
2016(22)				initial discharge	duration of antibiotic therapy.	
					Cases of sepsis with positive culture for	
					coagulase-negative staphylococci were	
					labelled only if the clinical course was	
					suggestive of sepsis and appropriate	
					antibiotic therapy was given.	
					Culture negative sensis:	
					Culture-negative sepsis.	
					Baby has ALL of the following:	
					1.Any one of the clinical sign/symptoms:	
					Difficulty feeding, convulsions, movement	
					only when stimulated, watery stools, pus	
					from umbilical stump, discharge (purulent)	
					from ear, temperature $(>37.5 \text{ °C or } <36.5)$	
					C), heart rate (>180 min or <100 min),	
					drawing grunting appeal capillary refill	
					time > 3 sec. cvanosis, lethargy/drowsiness,	
					bulging fontanel, abdominal distension,	
					multiple (>10) skin pustules,c linicians'	
					discretion	
					OR	
					Existence of predisposing risk factors:	
					maternal fever within 7 days before delivery	
					or foul smelling liquor or prolonged rupture	
					of membranes (>18 h)	

						OR Radiological evidence of pneumonia OR Positive septic screen 2.Blood culture not done or no organisms detected in blood 3.Physician institutes appropriate treatment for sepsis	
Kaushik, 1998(23)	India, South-East Asia Region	Middle	Not stated	Cohort study	Inborn, no exclusion criteria stated, subgroups: NBW, LBW	Clinical picture suggestive of septicaemia (definition according to Klein et al. 1990:(57) lethargy; mottled, pale skin; change in feeding pattern; vomiting)	EOS+LO S
Khatua, 1986(24)	India, South-East Asia Region	Middle	1982- 1983	Single center prospective cohort study, active observation	Calcutta Medical College, nursery, no exclusion criteria stated	Clinical manifestation and/or positive blood culture (table IV: refusal of feeds; lethargy; diarrhea; temperature change; abdominal distension; jaundice; vomiting; respiratory distress; sclerema; apneic spells; convulsion; hepatomegaly; splenomegaly)	EOS+LO S
Kiatchoosaku n, 2019(25)	Thailand, South-East Asia Region	Middle	2012- 2013	Multicenter retrospective cohort study, hospital records registry	3 Level II- and III-care hospitals: one university hospital, one regional hospital, one provincial hospital, NICUs, inborn, no exclusion criteria stated	Three or more clinical signs or laboratory results consistent with EOS, and further received antibiotics for at least 5 consecutive days. Clinical signs or laboratory results that suggested sepsis: (1) increased oxygen, requirement or ventilatory support, (2) increase in apneic or bradycardic episodes or tachycardia, (3) hypotension or	EOS (≤72h)

						 prolonged capillary refill time, (4) lethargy, (5) temperature instability, (6) ileus/feeding intolerance or abdominal distension, (7) glucose intolerance, and (8) base deficit >10 mmol/L 	
López, 2013(26)	Nicaragua, Region of the Americas	Middle	2009	Multicenter prospective trial, active observation	18 "health care centers", one of which a specialized, level III- care university hospital, no exclusion criteria stated	Clinical signs for neonatal sepsis: difficulty feeding; convulsions; hyperreactive; respiratory rate >60/min; subcostal indrawing; axillary temperature > 37.5C or < 35.5C (definition according to Carlin et al. 2008)(58)	EOS+LO S
Martin, 2007(27)	Antigua and Barbuda, Region of the Americas	High	1994- 2002	Single center retrospective cohort study, hospital records registry	The "only full service hospital" in the country, special care nursery, no exclusion criteria stated	Clinical features suggestive for sepsis (respiratory distress; fever, lethargy; poor feeding)	EOS+LO S
Mondal, 1991(28)	India, South-East Asia Region	Middle	1988- 1989	Single center prospective cohort study, active observation	Referral hospital, inborn, no exclusion criteria stated	Clinical criteria (poor activity; refusal of feeds; hypothermia; respiratory distress; abdominal distension; hepatosplenomegaly; hyperthermia; sclerema; seizures; jaundice; bronchopneumonia; bleeding manifestation; arthritis; shock) and/or positive blood culture The total and differential white blood cell count, platelet, band count and micro-ESR were estimated in all cases [] The neonates whose subsequent course and investigations did not reveal septicaemia were excluded from the study	EOS+LO S
Nazer,	Jordan,	Middle	1977	Single center	550-bedded university hospital,	Clinical criteria (definition according to	EOS+LO

1981(29)	Eastern Mediterranean Region		1978	prospective cohort study,	NICU, inborn,	Behrman 1975)(59)	S
NNPD Study Group, 2002(30)	India, South-East Asia Region	Middle	2000	Multicenter prospective cohort study	16 centers participating in the NNPD study group in India, no exclusion criteria stated	 Definition according to National Neonatal-Perinatal Database (60): Septicemia (systemic bacterial infection) culture negative (clinical): In an infant having clinical picture suggestive of septicemia, the presence of any one of the following criteria is enough for assigning probable diagnosis of infection: Existence of predisposing factors: maternal fever or foul smelling liquor or prolonged rupture of membranes (>24 hrs) or gastric polymorphs (>5 per high power field) Positive septic screen (two of the four parameters (TLC <5000/mm, band to total polymorph ratio of > 0.2, ANC<1800/mm³, CRP >1mg/dl, micro ESR>10mm 1st hour) Radiological evidences of pneumonia 	EOS+LO S
Pavan Kumar, 2017(31)	India, South-East Asia Region	Middle	2013-2015	Single center prospective cohort study, active observation	Level II-care rural hospital, 10- bedded Neonatal Intensive Care Unit (NICU), Inborn, exclusion criteria: gross congenital anomalies	Young Infant Study Algorithm standard definitions of sepsis, adapted from National Healthcare Safety Network which included tachypnea, respiratory distress, prolonged capillary refill time, abnormal color, abdominal distension, poor sucking, irritability, convulsions, temperature abnormalities, lethargy, or apnea and/or positive blood culture	EOS+LO S

Schrag, 2012(32)	South Africa, African Region	Middle	2004-2007	Single center prospective trial, active observation	Level II - III care academic hospital, inborn, exclusion criteria: planned cesarean section, intepartum hemorrhage, known severe congenital malformation, intrauterine death confirmed before randomization, known allergy to chlorhexidine, face presentation, significant genital warts or ulcers, full cervical dilatation at randomization and age <15 years; subgroups: preterm, VLBW, LBW;	Culture confirmed or clinical sepsis EOS (clinical): A neonate hospitalised on days 0-2 of life and who in the absence of another recognizable congenital infection had at least one laboratory criteria and either: respiratory distress (one criterion required) or at least two clinical criteria LOS (clinical): A neonate hospitalised between day three and 28 of life with at least one laboratory criteria and either: respiratory distress (two criteria required), OR one feature of respiratory distress and one other clinical criteria. Clinical criteria: respiratory distress; hypertension; pyrexia or hypothermia; abdominal/ feeding problems; bleeding diathesis, lethargy or irritability; central nervous system Laboratory criteria :TLC; ANC; platelet count; CRP; elevated CSF white blood cell	EOS+LO S, EOS (<48h), LOS (>48h)
			1007	Maria		Content 1)	
Shin, 2009(33)	South Korea, Western Pacific Region	High	1997 1998 1999	Multicenter retrospective cohort study, hospital records registry	4 Level II - III care hospitals, inborn and outborn, no exclusion criteria stated	Neonatal sepsis was defi ned as a clinical syndrome characterized by systemic signs of infection and/or accompanied by bacteremia Clinical sepsis was diagnosed when the doctor suspected it to be sepsis based on systemic symptoms and signs, such as temperature instability, lethargy, apnea, poor feeding, and respiratory or gastrointestinal disease (e.g. tachypnea and cyanosis or vomiting,	EOS+LO S

						diarrhea and abdominal distention), serology and/or radiology; TLC >30 000 cells/ L or <5000 cells/ L, CRP >1.0 mg/dL, risk factors for vertical transmission and/or intrapartum administration of antibiotics, and negative culture	
Swarnkar, 2012(34)	India, South-East Asia Region	Middle	2008-2010	Single center retrospective cohort study, hospital records registry	Rural hospital, no exclusion criteria stated	Neonates who were clinically suspected to have bacterial infections within the first 48 hours of life, based on the risk factors and/or clinical features, were subjected to various hematological screening parameters and blood cultures (buffy coat smear examination, CRP, micro-ESR, TLC, ANC, and Immature (band cells) count / Total neutrophil count ratio)	EOS (≤48h)
Turner, 2013(35)	Thailand/ Myanmar, South-East Asia Region	Middle	2009-2012	Single center prospective cohort study, active observation	Health center for malaria in a refugee camp, special baby care unit, inborn and outborn, exclusion criteria: severe congenital abnormality identified prenatally or at birth, or had received antibiotics within the early neonatal period (≤6 days of age)	Fever (>38°C on one occasion or >37.5°C on two occasions separated by at least one hour) or at least two clinical features (poor perfusion, respiratory distress, persisting glucose imbalance, abdominal distension, bilious aspirates, or blood in the stool in a baby <72 hours of age)	EOS (<7d)
Watson, 2003(36)	USA, Region of the Americas	High	1995	Multicenter retrospective cohort study, hospital records registry	All non-federal hospitals in several states, representative of the US, Inborn and outborn no exclusion criteria stated	ICD-based implicit case identification (ICD-9–CM codes for both infection and acute organ failure)	EOS+LO S

community-based									
Bang, 2001(37)	India, South-East Asia Region	Middle	1995- 1996	Prospective cohort study	Inborn and outborn no exclusion criteria stated	Simultaneous presence of any two of the following six criteria any time during 0-28 days: 1. Baby which cried well at birth, it's cry became weak or abnormal, or stopped crying; or baby who earlier sucked or licked well, stopped sucking or mother feels that sucking became weak or reduced: or baby who was earlier conscious and alert, became drowsy or unconscious; 2. Skin temperature >99°F or <95°F; 3. Sepsis in skin or umbilicus; 4. Diarrhea or persistent vomiting or distension of abdomen; 5. Grunt or severe chest indrawing; 6. Respiratory rate ≥ 60 / minute even on counting twice	EOS+LO S		
Bang, 2005(38)	India, South-East Asia Region	Middle	1996- 2003	Trial, active observation	Home-based surveillance by trained village health workers in rural communities in peripheral India, no exclusion criteria stated	 Simultaneous presence of any two or more criteria in a neonate denoted sepsis : A. Criteria used in 1995 to 1998: 1. Previously normal cry became weak/stopped or previously normal baby became drowsy/unconscious or previously normal sucking became weak or stopped. 2. Baby cold to touch or fever (skin temperature >99°F) 3. Skin infection or umbilical infection 4. Vomiting or diarrhea or abdominal distension 5. Respiratory rate ≥60 6. Grunt or chest indrawing B. Criteria used in 1998 to 2003: 	EOS+LO S		

						 Previously normal cry became weak/stopped Previously normal baby became drowsy/unconscious Previously normal sucking became weak/stopped Baby cold to touch or fever (>99°F) Skin infection or umbilical infection Abdominal distension or vomiting Grunt or chest indrawing 	
Bartlett, 1991(39)	Guatemala, Region of the Americas	Middle	1988- 1989	Prospective and retrospective cohort study	No exclusion criteria stated	Clinical diagnoses were assigned by the study physicians based on history and physical examination [] in most cases without laboratory examination	EOS+LO S
Kayom, 2018(40)	Uganda, African Region	Low	2012	Prospective and retrospective cohort study	Community based surveillance, referral of septic neonates to the emergency unit of the national referral hospital; inborn and outborn, exclusion criteria: gross congenital malformation and extremely low birthweight	WHO IMNCI criteria(61): Neonate that had temperature > 37.5°C or felt hot to touch, convulsions (by history), fast breathing (> 60 breaths/minute), severe chest indrawing, nasal flaring, grunting, bulging fontanelle, pus draining from ear, umbilical redness extending to the skin, feels cold (by history), many or severe skin pustules, difficult to wake up, cannot be calmed within 1 h, less than normal movement, not able to feed and not able to attach to breast or suck	EOS+LO S
Niswade, 2011(41)	India, South-East Asia Region	Middle	2006- 2007	Prospective cohort study	No exclusion criteria stated	Presumption of diagnosis based on the typical history of illness	EOS+LO S
Panigrahi, 2017(42)	India, South-East Asia Region	Middle	2002- 2005	Prospective cohort study	223 villages in rural India, inborn and outborn, exclusion criteria: >60 days old,	Clinical evaluation included specific questions and physical examination on the 12 signs/symptoms of sepsis adapted from the IMCI guidelines (62)	EOS+LO S (≤28d), EOS (≤72h), LOS

					congenital anomaly, not given consent	Only cases of clinical sepsis confirmed by a study paediatrician were included. Clinical sepsis included negative blood/CSF cultures or respiratory symptoms (pneumonia), when the infant was treated with antibiotics for 5 or more days or died within 5 days of enrolment.	(>72h≤28 d)
Raihana, 2017(43)	Bangladesh, South-East Asia Region	Middle	2013- 2015	Prospective trial	Inborn and outborn, exclusion criteria: women whose breastfeeding status was unknown or missing	Clinical sepsis definition according to "The Young-Infants Clinical Science Study Group"	EOS (<7d)

Abbreviations: ANC absolute neutrophil count, CRP C-reactive protein, CSF cerebrospinal fluid, EOS early-onset sepsis, ESR erythrocyte sedimentation rate, ICD International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification of Diseases and Related Health Problems, ICD-CM International Statistical Classification, IMCI Integrated Management of Childhood Illness, LOS late-onset sepsis, NBW/LBW/VLBW normal/low/ very low birth weight, NICU neonatal intensive care unit, NNPD National Neonatal-Perinatal Database, SD standard deviation, SIRS systemic inflammatory response syndrome, TLC total leucocyte count, WHO World Health Organisation

Supplement eTab. 2: Risk of bias of the included studies

Item	1.	2.	3.	4.	5.	6.	7.	8.	9.	10.	11. Summary item
Hartman, 2013	1	1	1	1	1	1	3	1	1	1	2
Shin, 2009	3	1	1	1	1	1	3	1	1	1	3
Watson, 2003	1	1	1	1	1	1	3	1	1	1	2
Turner, 2013	3	1	1	1	1	1	3	1	1	1	3
Niswade, 2011	3	1	1	1	1	3	3	1	1	1	3
Bang, 2001	3	1	1	1	1	1	3	1	1	1	3
Swarnkar, 2012	3	1	1	1	1	3	3	1	1	1	3
Bartlett, 1991	3	1	1	1	1	3	3	1	1	1	3
Bang, 2005	3	1	1	1	1	1	3	3	1	1	3
Chacko, 2005	3	1	1	1	1	3	3	1	1	1	3
Ghiorghis , 1997	3	1	1	1	1	3	3	1	1	1	3
Goulart, 2006	3	1	1	1	1	1	1	1	1	1	2
DeNIS investigators, 2016	3	1	1	1	1	3	3	1	1	1	3
Kaushik, 1998	3	1	1	1	1	3	3	1	1	1	3
Kayom, 2018	3	1	1	3	1	1	1	1	1	1	3
Khatua, 1986	3	1	1	1	1	3	3	1	1	1	3
Kiatchoosakun, 2019	3	1	1	1	1	1	3	1	1	1	3
López, 2013	3	1	1	1	1	3	3	1	1	1	3
Martin, 2007	1	1	1	1	1	3	3	1	1	1	2

Mondal, 1991	3	1	1	1	1	3	3	1	1	1	3
Nazer, 1981	3	1	1	1	1	3	3	1	1	1	3
Nnpd Study Grp, 2002	3	1	1	1	1	3	3	1	1	1	3
Panigrahi, 2017	3	1	1	3	1	1	1	1	1	1	3
Pavan Kumar, 2017	3	1	1	1	1	1	1	1	1	1	2
Raihana, 2017	3	3	1	3	1	1	1	1	1	1	3
Schrag, 2012	3	3	1	1	1	1	3	1	1	1	3

Hoy Risk of Bias Assessment

- 1. Was the study's target population a close representation of the national population in relation to relevant variables? (1=low/3=high risk of bias)
- 2. Was the sampling frame a true or close representation of the target population? (1=low/3=high risk of bias)
- 3. Was some form of random selection used to select the sample, OR was a census undertaken? (1=low/3=high risk of bias)
- 4. Was the likelihood of nonresponse bias minimal? (1=low/3=high risk of bias)
- 5. Were data collected directly from the subjects (as opposed to a proxy)? (1=low/3=high risk of bias)
- 6. Was an acceptable case definition used in the study? (1=low/3=high risk of bias)
- 7. Was the study instrument that measured the parameter of interest shown to have validity and reliability? (1=low/3=high risk of bias)
- 8. Was the same mode of data collection used for all subjects? (1=low/3=high risk of bias)

- 9. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1=low/3=high risk of bias)
- 10. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1=low/3=high risk of bias)
- 11. Summary item on the overall risk of study bias (1=low/2=moderate/3=high risk of bias)

Supplement eTab. 3: Underlying pathogens by sepsis type, 2000-2019

Number				
of	Gram-positive bacteria	Gram-negative bacteria	Funghi	Antimicrobial resistance
isolates				
909	Staphylococcus aureus 17:5%	Klebsiella pneumoniae 31·2%	Candida spp. 8.7%	Klebsiella penumoniae non-susceptible to: amikacin
	Staphylococcus albus 4.9%	<i>E coli</i> 10.5%		35.6%, ciprofloxacin 26.7%, ceftazidime 34.4%, gentamicin 78.6%, cefotaxime 78.5%;
		Pseudomonas spp 6.8%		
		Acinetobacter spp, 4.9%		
				Staphylococcus aureus non-susceptible to: vancomycin
				26.1%, amikacin 43.3%, cefotaxime 46.8%, penicillin
				89·3%, ampicillin 91·7%
28	Staphylococcus aureus 35.7%	Klebsiella spp . 21.4%		Gram-negative bacteria resistant to: ampicillin 100%,
				cloxacillin 64·7%, gentamicin 52·9%, piperacillin
	Nonhemolytic streptococci 3.5%	Untyped gram-negatives 21.4%		47.1%, linezolid 41.2%, ceftriaxone/cefotaxime 31.2%,
		F coli 10:7%		amikacin 17.6%, ciprofloxacin 11.8%, meropenem
				11.8%;
		Pseudomonas aeruginosa 3.5%		
		Non-fermenting gram-negatives 3.5%		
				Staphylococcus aureus resistant to: ampicillin 90%,
				cloxacillin 90%, piperacillin 30%, gentamicin 20%,
				ceftriaxone/cefotaxime 20%, ciprofloxacin 20%,
				linezolid 0%, amikacin 0%, meropenem 0%
1005	Coagulase-negative staphylococci	Acinetobacter spp, 22·1%		Gram-negative bacteria: Amikacin resistance:
	14.9%		Candida spp. 0.7%	Acinetobacter spp, 84%, Klebsiella spp. 45%, E coli
		Klebsiella spp. 16.8%		23%, Pseudomonas spp 17%, Enterobacter spp 36%
	909 228	Number Gram-positive bacteria 909 Staphylococcus aureus 17:5% Staphylococcus albus 4:9% Staphylococcus albus 4:9% 28 Staphylococcus aureus 35:7% Nonhemolytic streptococci 3:5% Nonhemolytic streptococci 3:5% 1005 Coagulase-negative staphylococci 14:9%	Number Gram-positive bacteria Gram-negative bacteria 909 Staphylococcus aureus 17:5% Klebsiella pneumoniae 31:2% Staphylococcus albus 4:9% E coli 10:5% Pseudomonas spp 6:8% Acinetobacter spp, 4:9% 28 Staphylococcus aureus 35:7% Klebsiella spp . 21:4% Nonhemolytic streptococci 3:5% Untyped gram-negatives 21:4% E coli 10:7% Pseudomonas aeruginosa 3:5% Non-fermenting gram-negatives 3:5% Non-fermenting gram-negatives 3:5% 1005 Coagulase-negative staphylococci Acinetobacter spp, 22:1% 14:9% Klebsiella spp. 16:8% 16:8%	Number of isolates Gram-positive bacteria Gram-negative bacteria Funghi 909 Staphylococcus aureus 17-5% Klebsiella pneumoniae 31-2% Candida spp. 8-7% Staphylococcus albus 4-9% E coli 10-5% Pseudomonas spp 6-8% Acinetobacter spp, 4-9% 28 Staphylococcus aureus 35-7% Klebsiella spp. 21-4% Untyped gram-negatives 21-4% 28 Staphylococcus aureus 35-7% Klebsiella spp. 21-4% E coli 10-7% 29 Nonhemolytic streptococci 3-5% Untyped gram-negatives 21-4% E coli 10-7% 20 Non-fermenting gram-negatives 3-5% Non-fermenting gram-negatives 3-5% Candida spp. 0-7% 1005 Coagulase-negative staphylococci 14-9% Acinetobacter spp, 22-1%

2016		Staphylococcus aureus 12·1%	E coli 13·6%	Meropenem resistance: Acinetobacter spp, 81%,
				Klebsiella spp. 36%, E coli 14%, Pseudomonas spp
		Enterococcus spp. 5.6%	Pseudomonas spp 6.8%	27%, Enterobacter spp 17%
		Streptococcus spp. 1.2%	Enterobacter spp 4·4%	
		Group B streptococci 0.8%		Colistin resistance: 1% of gram-negative isolates.
		Others 1.0%		
				Gram-positive bacteria:
				Amikacin resistance: coagulase-negative staphylococci 14%, <i>Staphylococcus aureus</i> 2%
				staphylococci 60%, <i>Staphylococcus aureus</i> 37%.
				Vancomycin resistance: <i>Enterococcus</i> spp 26%, coagulase-negative staphylococci 0%, <i>Staphylococcus</i> <i>aureus</i> 0%
Niswade, 2011	32	Streptococcus pneumoniae 25.0%	Klebsiella spp 21.9%	
		Staphylococcus aureus 25.0%	E coli 28·1%	
EOS	<u> </u>			
Chacko, 2005	15	Staphylococcus aureus 13.3%	Pseudomonas spp 60%,	
		Streptococcus viridans 7%	Klebsiella pneumoniae 13·3%	
			E coli 7%	
Kiatchoosakun, 2018	4	Streptococcus agalactiae 50%	E coli 25%	

			Pseudomonas spp 25%		
Turner, 2013	1		E coli 100%		
Swarnkar, 2012	37	Gram-positive organisms 43%	Gram-negative organisms 56.75%		
		Staphylococcus aureus 38%	Klebsiella pneumoniae 48·6%		
		other staphylococci 5·4%	E coli 13·5%		
Schrag, 2012	29	Group B streptococci 55.2%	E coli 6·9%		
		Enterococcus faecalis 10.3%	Acinetobacter baumannii 6.9%		
		Staphylococcus aureus 6.9%	Klebsiella pneumoniae 3·4%		
		Streptococcus viridans 6.9%	Acinetobacter lwoffii 3·4%		
Panigrahi, 2017	5		Klebsiella spp 40·0%		
			E coli 20·0%		
			other gram-negatives 40.0%		
LOS	•				
Panigrahi, 2017	54	Staphylococcus aureus 20.3%	Klebsiella spp 50·0%	Candida spp. 1.8%	
		other gram-positives 1.8%	E coli 12·3%		
			other gram-negatives 9.3%		
Schrag, 2012	20	Group B streptococci 25%	E coli 40%		
		Enterococcus faecium 10%	Klebsiella spp 10%		

Staphylococcus aureus 10%		
Streptococcus species 5%		

Abbreviations: EOS early-onset sepsis, LOS late-onset sepsis, E coli Escherichia coli